Preparation of Antibody-Modified mRNA-LNPs via a Combination of Post-Encapsulation and Post-Insertion
ACS Applied Bio Materials · 03.08.2026 · 9 (15) · 7157-7166
DOI: 10.1021/acsabm.6c00925 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, online erschienen am 23.07.2026. Verfasst von Yoshie Ri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai cit…. Hauptthemen laut MEDLINE: RNA, Messenger, Nanoparticles, Lipids, Biocompatible Materials. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Tohoku University.
Abstract (Originalsprache)
Using ligand-modified lipid nanoparticles (LNPs) to encapsulate messenger RNA (mRNA) has become an important modality for tissue/organ/cell-specific gene delivery. Modifying mRNA-LNPs either with antibodies or their derivatives (Ab-mRNA-LNPs) has emerged as a promising drug delivery system (DDS) due to its efficacy and target specificity. Manufacturing Ab-mRNA-LNPs, however, involves complex and multi-step procedures that include the encapsulation of mRNA followed by the anchoring of antibodies via polyethylene glycol (PEG) linker-conjugated lipids. In this work, we present a seamless strategy for the production of Ab-mRNA-LNPs by integrating the post-encapsulation of mRNA into mRNA-free LNPs (fLNPs) with a post-insertion of ligand-conjugated PEG-lipid (Lig-PEG-lipid). Using a T-cell-targeting model, we further describe how targeting efficacy is influenced by controlling the surface nature of the Ab-mRNA-LNPs either via the modification of PEG-lipids or by replacing the phospholipids. Modification of the DSPE-PEG-methoxy and employment of either DSPC or DPPC significantly improves the accumulation of Ab-mRNA-LNPs in T cells. These findings highlight the importance of LNP surface engineering.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai city, Miyagi980-8578, Japan.
- Life Science Research Laboratory, NOF CORPORATION, 3-3 Chidori-cho, Kawasaki-ku, Kawasaki City, Kanagawa210-0865, Japan.
ORCID-Profile: Hidetaka Akita
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Tohoku University
- NOF CORPORATION
Zitieren
APA
Ri, Y., Oshima, S., Tanaka, H., Sugawara, T., Hori, M., Junior, S. Y., Nakai, Y., Ito, K., Shimoya, K., Sakurai, Y., & Akita, H. (2026). Preparation of Antibody-Modified mRNA-LNPs via a Combination of Post-Encapsulation and Post-Insertion. ACS Applied Bio Materials, 9(15), 7157-7166. https://doi.org/10.1021/acsabm.6c00925
Vancouver
Ri Y, Oshima S, Tanaka H, Sugawara T, Hori M, Junior SY, et al. Preparation of Antibody-Modified mRNA-LNPs via a Combination of Post-Encapsulation and Post-Insertion. ACS Applied Bio Materials. 2026;9(15):7157-7166. doi:10.1021/acsabm.6c00925
BibTeX
@article{Ri2026,
author = {Ri, Yoshie and Oshima, Shion and Tanaka, Hiroki and Sugawara, Takumi and Hori, Mizuho and Junior, Siril Yves and Nakai, Yuta and Ito, Kasumi and Shimoya, Kazuto and Sakurai, Yu and Akita, Hidetaka},
title = {Preparation of Antibody-Modified mRNA-LNPs via a Combination of Post-Encapsulation and Post-Insertion},
journal = {ACS Applied Bio Materials},
year = {2026},
volume = {9},
number = {15},
pages = {7157--7166},
doi = {10.1021/acsabm.6c00925}
}
EUVIMED